CDC officials said."We began to hear how the guidelines were being misused and misapplied" said the CDC's Christopher Jones, a co-author of the draft guidance.The proposed changes, contained in a 229-page draft update in the Federal Register, would roll back some suggested limits on the drugs.
Their publication opens a 60-day public comment period. The CDC will consider comments before finalizing the updated guidance.The general intent is to foster individualized patient care, Jones said.
It also offers more options for treating the kind of short-term, acute pain that follows surgeries or injuries.One expert expressed initial wariness about a proposed revision.Close-up of an opened prescription bottle, labelled as containing the opioid hydrocodone, as a number of its pills lie on a white surface, March 14, 2017. (Photo by Tom Kelley/Getty Images) The 2016 guidance succeeded in helping to reduce inappropriate and dangerous prescribing, said Dr.
Adriane Fugh-Berman of Georgetown University Medical Center. Its critics have included pain patients, but also painkiller manufacturers and groups they fund, she said."There was nothing wrong with the original guidelines," said Fugh-Berman, a paid expert witness for plaintiffs in cases targeting pharmaceutical marketing practices.Dr.